In order to reveal biological mechanisms underlying clinical outcome of high-grade serous (HGS) epithelial ovarian carcinomas (EOC), we evaluated the association between tumor epigenetic changes and time to recurrence. We assessed methylation at approximately 450,000 genome-wide CpGs in tumors of 337 Mayo Clinic patients. Semi-supervised clustering of discovery (n=168) and validation (n=169) sets was used to determine clinically relevant methylation classes. Clustering identified two methylation classes based on 60 informative CpGs, which differed in time to recurrence in the validation set (R versus L class, p =2.9×10−3, HR =0.52, 95% CI=0.34, 0.80). Follow-up analyses considered genome-wide tumor mRNA expression (n=104) and CD8 T cell infiltration (n=89) in patient subsets. Hypo-methylation of CpGs located in 6p21.3 in the R class associated with cis up-regulation of genes enriched in immune response processes (TAP1, PSMB8, PSMB9, HLA-DQB1, HLA-DQB2, HLA-DMA, and HLA-DOA), increased CD8 T-cell tumor infiltration (p=7.6 × 10−5), and trans regulation of genes in immune-related pathways (p=1.6 × 10−32). This is the most comprehensive assessment of clinical outcomes with regard to EOC tumor methylation to date. Collectively, these results suggest that an epigenetically mediated immune response is a predictor of recurrence and, possibly, treatment response for HGS EOC.